ClinicalTrials.gg
RecruitingNCT05556928CARE-HemeUpdated Dec 8, 2025

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

An observational study in Multiple Myeloma, Amyloidosis and Plasma Cell Leukemia, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Primary conditionLeukemia, Plasma CellRegistry: Multiple MyelomaReclassifiedWhy we changed it
Registry
Multiple Myeloma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Plasma Cell
Why
  1. The study's listed conditions name Leukemia, Plasma Cell, a narrower term within Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Alabama at Birmingham · Observational

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Leukemia, Plasma Cell with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Leukemia, Plasma Cell · United States.

Started
2020
the only one that year
Observational
2 of 31
2 open now
Registered
27th of 31
by date

Among the 31 studies in Leukemia, Plasma Cell with a site in United States, this one is the only one that started in 2020, is one of 2 observational ones, and was the 27th registered.

Leukemia, Plasma Cell

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Open to participants now

8 of the 31 studies in Leukemia, Plasma Cell with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Leukemia, Plasma Cell studies recruiting now, 12 (41%) set no upper age limit and 13 (45%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 50 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Leukemia, Plasma Cell with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.

Read the detailed description

All participants will be invited to participate in a patient reported geriatric assessment questionnaire as well as an objective physical function testing. This includes the Short Physical Performance Battery (SPPB) that evaluates lower extremity performance and muscle strength assessment via hand grip dynamometer. Participants will also complete a 12 item modified version of PRO-CTCAE. This will be administered by trained research staff at the time of study enrollment. Repeat CARE instruments (Follow-up GA questionnaire and Physical Function test) will be administered after the baseline visit to measure changes in patient reported outcomes at 3 months, 6 months, and one year. A one-time blood or saliva sample will be requested and obtained at baseline or a follow-up visit.

03

Conditions studied

  • Multiple Myeloma
  • Amyloidosis
  • Plasma Cell Leukemia

Browse trials for

04

In context

Leukemia, Plasma Cell Reclassified

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Compared within Leukemia, Plasma Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Myeloma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients ≥50 years of age with a diagnosis of any Hematologic Malignancy having an appointment at any participating UAB entity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients are ≥50 years of age.
  • Patients have a proven diagnosis of Hematologic (Multiple Myeloma, AL Amyloidosis, Waldenstrom's Macrogloblunemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic syndromes, Myeloproliferative Neoplasm, Acute/Chronic Myeloid Leukemia, Acute/Chronic Lymphoid Leukemia).
  • Patients have appointments at UAB including if they are an inpatient or other clinic locations.

Exclusion criteria

Exclusion Criteria:

  • Individuals who are \<50 years old.
  • Patients who do not read and/or speak English will not be eligible for this study as many of the questionnaires are not validated in other languages. No exclusions will be made based on gender, ethnicity or race.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. Create the CARE-Heme Registry

    To establish and maintain a well-annotated registry (to be called the 'CARE-Heme' Registry) of adults ≥50 years of age with a hematologic malignancy to improve our understanding of this vulnerable population.

    Time frame: 5 years

Secondary outcomes

  1. To administer a patient reported geriatric assessment and a brief objective physical assessment.

    To measure the proportion of patients with overall and domain-specific geriatric impairments, the proportion of patients with Myopenia, and the proportion of patients with frailty.

    Time frame: 5 years

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2020 (actual). Primary completion is estimated for Dec 2027, 89 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2022
First posted
Sep 27, 2022
StartActual
Jul 21, 2020
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05556928
Responsible party
Noha Mohamed Sharafeldin (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Sep 27, 2022
Start date
Jul 21, 2020
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 8, 2025

Study contacts

Landon Martin, BS
Contact
landoncmartin@uabmc.edu
(205) 638-2120

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion